Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 5/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1892450 | 0.87 | PPARG (0.49) | PPARGAGTR1ACHEAGTR2EDNRA | |
| SCHEMBL1897246 | 0.85 | PPARG (0.47) | PPARGAGTR1ACHE | |
| SCHEMBL1893340 | 0.85 | PPARG (0.51) | PPARGAGTR1ACHE | |
| SCHEMBL13626121 | 0.83 | PPARG (0.52) | PPARGAGTR1ACHEAGTR2 | |
| SCHEMBL1888964 | 0.83 | PPARG (0.64) | PPARGAGTR1ACHE | |
| SCHEMBL1893370 | 0.82 | PPARG (0.52) | PPARGAGTR1ACHEAGTR2EDNRA | |
| SCHEMBL1898749 | 0.81 | PPARG (0.46) | PPARGAGTR1ACHE | |
| SCHEMBL1890122 | 0.81 | PPARG (0.61) | PPARGAGTR1ACHE | |
| SCHEMBL1893927 | 0.80 | PPARG (0.55) | PPARGAGTR1ACHEAGTR2 | |
| SCHEMBL1892572 | 0.79 | PPARG (0.47) | PPARGAGTR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207654-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207654-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | C1R, C3AR1, C1S | PPARG 3372/4885AGTR1 22/4885ACHE 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.